About
Immuno-oncology antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySeattle/Pacific Northwest
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
640
By Phase
PHASE1/PHASE2: 2PHASE1: 1
By Status
RECRUITING: 2UNKNOWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06090266Lead Sponsor
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
PHASE1/PHASE2Recruiting
168 participants
Started: Oct 24, 2023 · Completed: Feb 1, 2027
NCT05094804Lead Sponsor
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
PHASE1/PHASE2Recruiting
172 participants
Started: Sep 9, 2021 · Completed: Aug 15, 2024
NCT01022333Collaborator
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
PHASE1Unknown
300 participants
Started: Jul 31, 2009 · Completed: Dec 31, 2010
Locations (1)
Headquarters
Seattle, WA, United States
Map
Loading map...